PRODUCT NAME

Ipilimumab Biosimilar - Research Grade

SPECIES REACTIVITY

Human

HOST

Humanized

SPECIFICITY

Detects human CTLA-4. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. This product is for research use only.

PURIFICATION METHOD

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

ANTIGEN DISTRIBUTION

IMMUNOGEN

CONCENTRATION

FORMULATION

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

PURITY

>95% by SDS-PAGE and HPLC

ENDOTOXIN

≤ 0.75 EU/mg as determined by the LAL method

AGGRIGATION

STORAGE CONDITION

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

TARGET

CTLA-4

CLONE

SYNONYMS

BACKGROUND

Ipilimumab biosimilar is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab biosimilar is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab biosimilar is produced in mammalian (Chinese hamster ovary) cell culture.

UNIPROT

PATHOGEN TEST

APPLICATIONS

APPLICATION NOTES

USAGE

Products are for research use only. Not for use in diagnostic or therapeutic procedures.